In a relevant fact sent to the CNMV, the company reports the closing of the agreement with Panasonic Healthcare for the sale of its diabetes care business.
Bayer has closed the agreement to sell the Care diabetes business to Panasonic Healthcare Holdings for a total of 132,000 million yen, (around 1 billion euros), which includes blood glucose analysis systems and puncture devices for peopleWith this disease.
The Diabetes Care business represented 909 million euros in sales in 2014 and includes the portfolio of glucose meters and 'contour' reactive strips and other products such as 'Breeze 2' and 'Elite', and the puncture devices 'Microlet'.
The new Independent Diabetes Care company is called Evenia Diabetes Care Holding and the central headquarters is in Basel (Switzerland), Bayer reported in a statement.Panasonic Healthcare is backed by funds from the international investment firm KKR and Panasonic Corporation.